1887

Journal of Medical Microbiology logo

Volume 60, Issue 8

The host immune response to Open Access

Abstract

is the most common cause of nosocomial bacterial diarrhoea in the Western world. Diarrhoea and colitis are caused by the actions of toxins A and B released by pathogenic strains of . Adaptive immune responses to these toxins influence the outcomes of infection (CDI). Symptomless carriers of toxinogenic and those with a single episode of CDI without recurrence show more robust antitoxin immune responses than those with symptomatic and recurrent disease. Immune-based approaches to CDI therapy and prevention have been developed using active vaccination or passive immunotherapy targeting toxins. Innate immune responses to and its toxins are also central to the pathophysiology of CDI. An acute intestinal inflammatory response with prominent neutrophil infiltration and associated tissue injury is characteristic of CDI. Furthermore, inhibiting this acute inflammatory response can protect against the intestinal injury that results from exposure to toxins in animal models. Studies examining host risk factors for CDI have led to validated clinical prediction tools for risk of primary and of recurrent disease. Risk factors associated with severe CDI with poor clinical outcomes have also been identified and include marked elevation of the peripheral white blood cell count and elevated creatinine. However, further work is needed in this area to guide the clinical application of new approaches to disease prevention and treatment including new antimicrobials as well as passive and active immunization.

  • Published Online:
© 2011 SGM
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.030015-0
2011-08-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/8/1070.html?itemId=/content/journal/jmm/10.1099/jmm.0.030015-0&mimeType=html&fmt=ahah

References

  1. Aboudola S., Kotloff K. L., Kyne L., Warny M., Kelly E. C., Sougioultzis S., Giannasca P. J., Monath T. P., Kelly C. P. 2003; Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 71:1608–1610 [View Article][PubMed]
     [Google Scholar]
  2. Abougergi M. S., Broor A., Cui W., Jaar B. G. 2010; Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med 5:E1–E9 [View Article][PubMed]
     [Google Scholar]
  3. Anton P. M., Gay J., Mykoniatis A., Pan A., O’Brien M., Brown D., Karalis K., Pothoulakis C. 2004; Corticotropin-releasing hormone (CRH) requirement in Clostridium difficile toxin A-mediated intestinal inflammation. Proc Natl Acad Sci U S A 101:8503–8508 [View Article][PubMed]
     [Google Scholar]
  4. Aronsson B., Granström M., Möllby R., Nord C. E. 1985; Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 13:97–101 [View Article][PubMed]
     [Google Scholar]
  5. Babcock G. J., Broering T. J., Hernandez H. J., Mandell R. B., Donahue K., Boatright N., Stack A. M., Lowy I., Graziano R. et al. 2006; Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74:6339–6347 [View Article][PubMed]
     [Google Scholar]
  6. Brun P., Scarpa M., Grillo A., Palù G., Mengoli C., Zecconi A., Spigaglia P., Mastrantonio P., Castagliuolo I. 2008; Clostridium difficile TxAC314 and SLP-36kDa enhance the immune response toward a co-administered antigen. J Med Microbiol 57:725–731 [View Article][PubMed]
     [Google Scholar]
  7. Calabi E., Calabi F., Phillips A. D., Fairweather N. F. 2002; Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun 70:5770–5778 [View Article][PubMed]
     [Google Scholar]
  8. Chae S., Eckmann L., Miyamoto Y., Pothoulakis C., Karin M., Kagnoff M. F. 2006; Epithelial cell I kappa B-kinase beta has an important protective role in Clostridium difficile toxin A-induced mucosal injury. J Immunol 177:1214–1220[PubMed] [CrossRef]
     [Google Scholar]
  9. Chaves-Olarte E., Freer E., Parra A., Guzmán-Verri C., Moreno E., Thelestam M. 2003; R-Ras glucosylation and transient RhoA activation determine the cytopathic effect produced by toxin B variants from toxin A-negative strains of Clostridium difficile . J Biol Chem 278:7956–7963 [View Article][PubMed]
     [Google Scholar]
  10. Chen X., Kokkotou E. G., Mustafa N., Bhaskar K. R., Sougioultzis S., O’Brien M., Pothoulakis C., Kelly C. P. 2006; Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 281:24449–24454 [View Article][PubMed]
     [Google Scholar]
  11. Cloud J., Noddin L., Pressman A., Hu M., Kelly C. 2009; Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin Gastroenterol Hepatol 7:868–873.e2 [View Article][PubMed]
     [Google Scholar]
  12. Cohen S. H., Gerding D. N., Johnson S., Kelly C. P., Loo V. G., McDonald L. C., Pépin J., Wilcox M. H. 2010; Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31:431–455 [View Article][PubMed]
     [Google Scholar]
  13. Corthier G., Muller M. C., Wilkins T. D., Lyerly D., L’Haridon R. 1991; Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun 59:1192–1195[PubMed]
     [Google Scholar]
  14. Cottrell G. S., Amadesi S., Pikios S., Camerer E., Willardsen J. A., Murphy B. R., Caughey G. H., Wolters P. J., Coughlin S. R. et al. 2007; Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis. Gastroenterology 132:2422–2437 [View Article][PubMed]
     [Google Scholar]
  15. Crobach M. J., Dekkers O. M., Wilcox M. H., Kuijper E. J. 2009; European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 15:1053–1066 [View Article][PubMed]
     [Google Scholar]
  16. Drudy D., Calabi E., Kyne L., Sougioultzis S., Kelly E., Fairweather N., Kelly C. P. 2004; Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol 41:237–242 [View Article][PubMed]
     [Google Scholar]
  17. Drudy D., Harnedy N., Fanning S., O’Mahony R., Kyne L. 2007; Isolation and characterisation of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland. Clin Microbiol Infect 13:298–304 [View Article][PubMed]
     [Google Scholar]
  18. Fernie D. S., Thomson R. O., Batty I., Walker P. D. 1983; Active and passive immunization to protect against antibiotic associated caecitis in hamsters. Dev Biol Stand 53:325–332[PubMed]
     [Google Scholar]
  19. Gardiner D. F., Rosenberg T., Zaharatos J., Franco D., Ho D. D. 2009; A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 27:3598–3604 [View Article][PubMed]
     [Google Scholar]
  20. Garey K. W., Sethi S., Yadav Y., DuPont H. L. 2008; Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 70:298–304 [View Article][PubMed]
     [Google Scholar]
  21. Genth H., Dreger S. C., Huelsenbeck J., Just I. 2008; Clostridium difficile toxins: more than mere inhibitors of Rho proteins. Int J Biochem Cell Biol 40:592–597 [View Article][PubMed]
     [Google Scholar]
  22. Ghose C., Kalsy A., Sheikh A., Rollenhagen J., John M., Young J., Rollins S. M., Qadri F., Calderwood S. B. et al. 2007; Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun 75:2826–2832 [View Article][PubMed]
     [Google Scholar]
  23. Giannasca P. J., Zhang Z. X., Lei W. D., Boden J. A., Giel M. A., Monath T. P., Thomas W. D. Jr 1999; Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 67:527–538[PubMed]
     [Google Scholar]
  24. Howell M. D., Novack V., Grgurich P., Soulliard D., Novack L., Pencina M., Talmor D. 2010; Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 170:784–790 [View Article][PubMed]
     [Google Scholar]
  25. Hu M. Y., Katchar K., Kyne L., Maroo S., Tummala S., Dreisbach V., Xu H., Leffler D. A., Kelly C. P. 2009; Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136:1206–1214 [View Article][PubMed]
     [Google Scholar]
  26. Jefferson K. K., Smith M. F. Jr, Bobak D. A. 1999; Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. J Immunol 163:5183–5191[PubMed]
     [Google Scholar]
  27. Johnson S., Gerding D. N., Janoff E. N. 1992; Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile . J Infect Dis 166:1287–1294 [View Article][PubMed]
     [Google Scholar]
  28. Just I., Selzer J., Wilm M., von Eichel-Streiber C., Mann M., Aktories K. 1995; Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375:500–503 [View Article][PubMed]
     [Google Scholar]
  29. Katchar K., Taylor C. P., Tummala S., Chen X., Sheikh J., Kelly C. P. 2007; Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin Gastroenterol Hepatol 5:707–713 [View Article][PubMed]
     [Google Scholar]
  30. Kelly C. P., LaMont J. T. 2008; Clostridium difficile – more difficult than ever. N Engl J Med 359:1932–1940 [View Article][PubMed]
     [Google Scholar]
  31. Kelly C. P., Pothoulakis C., Orellana J., LaMont J. T. 1992; Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology 102:35–40[PubMed]
     [Google Scholar]
  32. Kelly C. P., Becker S., Linevsky J. K., Joshi M. A., O’Keane J. C., Dickey B. F., LaMont J. T., Pothoulakis C. 1994; Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest 93:1257–1265 [View Article][PubMed]
     [Google Scholar]
  33. Kelly C. P., Pothoulakis C., Vavva F., Castagliuolo I., Bostwick E. F., O’Keane J. C., Keates S., LaMont J. T. 1996; Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother 40:373–379[PubMed]
     [Google Scholar]
  34. Kim K., Pickering L. K., DuPont H. L., Sullivan N., Wilkins T. 1984; In vitro and in vivo neutralizing activity of human colostrum and milk against purified toxins A and B of Clostridium difficile . J Infect Dis 150:57–62 [View Article][PubMed]
     [Google Scholar]
  35. Kim P. H., Iaconis J. P., Rolfe R. D. 1987; Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun 55:2984–2992[PubMed]
     [Google Scholar]
  36. Kim H., Rhee S. H., Kokkotou E., Na X., Savidge T., Moyer M. P., Pothoulakis C., LaMont J. T. 2005; Clostridium difficile toxin A regulates inducible cyclooxygenase-2 and prostaglandin E2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAPK. J Biol Chem 280:21237–21245 [View Article][PubMed]
     [Google Scholar]
  37. Kim H., Rhee S. H., Pothoulakis C., Lamont J. T. 2007; Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. Gastroenterology 133:875–886 [View Article][PubMed]
     [Google Scholar]
  38. Kink J. A., Williams J. A. 1998; Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66:2018–2025[PubMed]
     [Google Scholar]
  39. Kokkotou E., Espinoza D. O., Torres D., Karagiannides I., Kosteletos S., Savidge T., O’Brien M., Pothoulakis C. 2009; Melanin-concentrating hormone (MCH) modulates C difficile toxin A-mediated enteritis in mice. Gut 58:34–40 [View Article][PubMed]
     [Google Scholar]
  40. Kotloff K. L., Wasserman S. S., Losonsky G. A., Thomas W. Jr, Nichols R., Edelman R., Bridwell M., Monath T. P. 2001; Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 69:988–995 [View Article][PubMed]
     [Google Scholar]
  41. Kuehne S. A., Cartman S. T., Heap J. T., Kelly M. L., Cockayne A., Minton N. P. 2010; The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711–713 [View Article][PubMed]
     [Google Scholar]
  42. Kyne L., Warny M., Qamar A., Kelly C. P. 2000; Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342:390–397 [View Article][PubMed]
     [Google Scholar]
  43. Kyne L., Warny M., Qamar A., Kelly C. P. 2001; Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189–193 [View Article][PubMed]
     [Google Scholar]
  44. Kyne L., Sougioultzis S., McFarland L. V., Kelly C. P. 2002; Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 23:653–659 [View Article][PubMed]
     [Google Scholar]
  45. Lamontagne F., Labbé A. C., Haeck O., Lesur O., Lalancette M., Patino C., Leblanc M., Laverdière M., Pépin J. 2007; Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 245:267–272 [View Article][PubMed]
     [Google Scholar]
  46. Leav B. A., Blair B., Leney M., Knauber M., Reilly C., Lowy I., Gerding D. N., Kelly C. P., Katchar K., Baxter R. 2010; Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965–969 [View Article][PubMed]
     [Google Scholar]
  47. Lee B. Y., Popovich M. J., Tian Y., Bailey R. R., Ufberg P. J., Wiringa A. E., Muder R. R. 2010; The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 28:5245–5253 [View Article][PubMed]
     [Google Scholar]
  48. Leung D. Y., Kelly C. P., Boguniewicz M., Pothoulakis C., LaMont J. T., Flores A. 1991; Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 118:633–637 [View Article][PubMed]
     [Google Scholar]
  49. Libby J. M., Jortner B. S., Wilkins T. D. 1982; Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun 36:822–829[PubMed]
     [Google Scholar]
  50. Linevsky J. K., Pothoulakis C., Keates S., Warny M., Keates A. C., Lamont J. T., Kelly C. P. 1997; IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol 273:G1333–G1340[PubMed]
     [Google Scholar]
  51. Loo V. G., Poirier L., Miller M. A., Oughton M., Libman M. D., Michaud S., Bourgault A. M., Nguyen T., Frenette C. et al. 2005; A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442–2449 [View Article][PubMed]
     [Google Scholar]
  52. Lowy I., Molrine D. C., Leav B. A., Blair B. M., Baxter R., Gerding D. N., Nichol G., Thomas W. D. Jr, Leney M. et al. 2010; Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197–205 [View Article][PubMed]
     [Google Scholar]
  53. Lyerly D. M., Saum K. E., MacDonald D. K., Wilkins T. D. 1985; Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 47:349–352[PubMed]
     [Google Scholar]
  54. Lyerly D. M., Johnson J. L., Frey S. M., Wilkins T. D. 1990; Vaccination against lethal Clostridium difficile enterocolitis with a nontoxic recombinant peptide of toxin A. Curr Microbiol 21:29–32 [View Article]
     [Google Scholar]
  55. Lyerly D. M., Bostwick E. F., Binion S. B., Wilkins T. D. 1991; Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 59:2215–2218[PubMed]
     [Google Scholar]
  56. Lyras D., O’Connor J. R., Howarth P. M., Sambol S. P., Carter G. P., Phumoonna T., Poon R., Adams V., Vedantam G. et al. 2009; Toxin B is essential for virulence of Clostridium difficile . Nature 458:1176–1179 [View Article][PubMed]
     [Google Scholar]
  57. Mattila E., Anttila V. J., Broas M., Marttila H., Poukka P., Kuusisto K., Pusa L., Sammalkorpi K., Dabek J. et al. 2008; A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis 40:702–708 [View Article][PubMed]
     [Google Scholar]
  58. McDonald L. C., Owings M., Jernigan D. B. 2006; Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12:409–415[PubMed] [CrossRef]
     [Google Scholar]
  59. Mulligan M. E., Miller S. D., McFarland L. V., Fung H. C., Kwok R. Y. 1993; Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile . Clin Infect Dis 16:Suppl. 4S239–S244 [View Article][PubMed]
     [Google Scholar]
  60. Nakamura S., Mikawa M., Nakashio S., Takabatake M., Okado I., Yamakawa K., Serikawa T., Okumura S., Nishida S. 1981; Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol 25:345–351[PubMed] [CrossRef]
     [Google Scholar]
  61. Ní Eidhin D. B., O’Brien J. B., McCabe M. S., Athié-Morales V., Kelleher D. P. 2008; Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol Med Microbiol 52:207–218 [View Article][PubMed]
     [Google Scholar]
  62. O’Donoghue C., Kyne L. 2010; Update on Clostridium difficile infection. Curr Opin Gastroenterol [Epub ahead of print] PMID: 21099432 [PubMed]
     [Google Scholar]
  63. O’Horo J., Safdar N. 2009; The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. Int J Infect Dis 13:663–667 [View Article][PubMed]
     [Google Scholar]
  64. Péchiné S., Janoir C., Collignon A. 2005a; Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J Clin Microbiol 43:5018–5025 [View Article][PubMed]
     [Google Scholar]
  65. Péchiné S., Gleizes A., Janoir C., Gorges-Kergot R., Barc M. C., Delmée M., Collignon A. 2005b ). Immunological properties of surface proteins of Clostridium difficile . J Med Microbiol 54:193–196 [View Article][PubMed]
     [Google Scholar]
  66. Péchiné S., Janoir C., Boureau H., Gleizes A., Tsapis N., Hoys S., Fattal E., Collignon A. 2007; Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile . Vaccine 25:3946–3954 [View Article][PubMed]
     [Google Scholar]
  67. Pépin J., Valiquette L., Alary M. E., Villemure P., Pelletier A., Forget K., Pépin K., Chouinard D. 2004; Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466–472[PubMed] [CrossRef]
     [Google Scholar]
  68. Pépin J., Valiquette L., Gagnon S., Routhier S., Brazeau I. 2007; Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 102:2781–2788 [View Article][PubMed]
     [Google Scholar]
  69. Pepin J., Vo T. T., Boutros M., Marcotte E., Dial S., Dubé S., Vasilevsky C. A., McFadden N., Patino C., Labbé A. C. 2009; Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis Colon Rectum 52:400–405 [View Article][PubMed]
     [Google Scholar]
  70. Pothoulakis C., Karmeli F., Kelly C. P., Eliakim R., Joshi M. A., O’Keane C. J., Castagliuolo I., LaMont J. T., Rachmilewitz D. 1993; Ketotifen inhibits Clostridium difficile toxin A-induced enteritis in rat ileum. Gastroenterology 105:701–707[PubMed]
     [Google Scholar]
  71. Redelings M. D., Sorvillo F., Mascola L. 2007; Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 13:1417–1419[PubMed] [CrossRef]
     [Google Scholar]
  72. Riegler M., Sedivy R., Pothoulakis C., Hamilton G., Zacherl J., Bischof G., Cosentini E., Feil W., Schiessel R., LaMont J. T. 1995; Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 95:2004–2011 [View Article][PubMed]
     [Google Scholar]
  73. Ryan E. T., Butterton J. R., Smith R. N., Carroll P. A., Crean T. I., Calderwood S. B. 1997; Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun 65:2941–2949[PubMed]
     [Google Scholar]
  74. Sánchez-Hurtado K., Corretge M., Mutlu E., McIlhagger R., Starr J. M., Poxton I. R. 2008; Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls. J Med Microbiol 57:717–724 [View Article][PubMed]
     [Google Scholar]
  75. Savidge T. C., Pan W. H., Newman P., O’Brien M., Anton P. M., Pothoulakis C. 2003; Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125:413–420 [View Article][PubMed]
     [Google Scholar]
  76. Sougioultzis S., Kyne L., Drudy D., Keates S., Maroo S., Pothoulakis C., Giannasca P. J., Lee C. K., Warny M. et al. 2005; Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128:764–770 [View Article][PubMed]
     [Google Scholar]
  77. Stubbe H., Berdoz J., Kraehenbuhl J. P., Corthésy B. 2000; Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing Clostridium difficile toxin A damaging of T84 monolayers. J Immunol 164:1952–1960[PubMed] [CrossRef]
     [Google Scholar]
  78. Sun X., He X., Tzipori S., Gerhard R., Feng H. 2009; Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-alpha by macrophages. Microb Pathog 46:298–305 [View Article][PubMed]
     [Google Scholar]
  79. Torres J. F., Lyerly D. M., Hill J. E., Monath T. P. 1995; Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun 63:4619–4627[PubMed]
     [Google Scholar]
  80. van Dissel J. T., de Groot N., Hensgens C. M., Numan S., Kuijper E. J., Veldkamp P., van ’t Wout J. 2005; Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 54:197–205 [View Article][PubMed]
     [Google Scholar]
  81. Venuto C., Butler M., Ashley E. D., Brown J. 2010; Alternative therapies for Clostridium difficile infections. Pharmacotherapy 30:1266–1278 [View Article][PubMed]
     [Google Scholar]
  82. Viscidi R., Laughon B. E., Yolken R., Bo-Linn P., Moench T., Ryder R. W., Bartlett J. G. 1983; Serum antibody response to toxins A and B of Clostridium difficile . J Infect Dis 148:93–100 [View Article][PubMed]
     [Google Scholar]
  83. von Eichel-Streiber C., Boquet P., Sauerborn M., Thelestam M. 1996; Large clostridial cytotoxins – a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol 4:375–382 [View Article][PubMed]
     [Google Scholar]
  84. Wada N., Nishida N., Iwaki S., Ohi H., Miyawaki T., Taniguchi N., Migita S. 1980; Neutralizing activity against Clostridium difficile toxin in the supernatants of cultured colostral cells. Infect Immun 29:545–550[PubMed]
     [Google Scholar]
  85. Ward S. J., Douce G., Dougan G., Wren B. W. 1999; Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile . Infect Immun 67:5124–5132[PubMed]
     [Google Scholar]
  86. Warny M., Vaerman J. P., Avesani V., Delmée M. 1994; Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 62:384–389[PubMed]
     [Google Scholar]
  87. Warny M., Fatimi A., Bostwick E. F., Laine D. C., Lebel F., LaMont J. T., Pothoulakis C., Kelly C. P. 1999; Bovine immunoglobulin concentrate-Clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 44:212–217 [View Article][PubMed]
     [Google Scholar]
  88. Warny M., Keates A. C., Keates S., Castagliuolo I., Zacks J. K., Aboudola S., Qamar A., Pothoulakis C., LaMont J. T., Kelly C. P. 2000; p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest 105:1147–1156 [View Article][PubMed]
     [Google Scholar]
  89. Wilcox M. H. 2004; Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 53:882–884 [View Article][PubMed]
     [Google Scholar]
  90. Wright A., Drudy D., Kyne L., Brown K., Fairweather N. F. 2008; Immunoreactive cell wall proteins of Clostridium difficile identified by human sera. J Med Microbiol 57:750–756 [View Article][PubMed]
     [Google Scholar]
  91. Yoshida M., Masuda A., Kuo T. T., Kobayashi K., Claypool S. M., Takagawa T., Kutsumi H., Azuma T., Lencer W. I., Blumberg R. S. 2006; IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity. Springer Semin Immunopathol 28:397–403 [View Article][PubMed]
     [Google Scholar]
  92. Zar F. A., Bakkanagari S. R., Moorthi K. M., Davis M. B. 2007; A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45:302–307 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.030015-0
Loading

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error